What is Leerink Partnrs' Estimate for TNDM FY2027 Earnings?

Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) - Equities researchers at Leerink Partnrs issued their FY2027 earnings per share estimates for Tandem Diabetes Care in a report released on Tuesday, October 15th. Leerink Partnrs analyst M. Kratky forecasts that the medical device company will post earnings per share of ($0.01) for the year. The consensus estimate for Tandem Diabetes Care's current full-year earnings is ($1.76) per share. Leerink Partnrs also issued estimates for Tandem Diabetes Care's FY2028 earnings at $0.27 EPS.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The medical device company reported ($0.47) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. Tandem Diabetes Care had a negative return on equity of 41.54% and a negative net margin of 17.15%. The company had revenue of $221.90 million during the quarter, compared to the consensus estimate of $205.63 million. During the same period in the previous year, the business earned ($0.30) EPS. Tandem Diabetes Care's revenue for the quarter was up 13.3% on a year-over-year basis.

TNDM has been the topic of a number of other research reports. UBS Group raised Tandem Diabetes Care to a "hold" rating in a report on Friday, August 2nd. Robert W. Baird boosted their price target on Tandem Diabetes Care from $36.00 to $39.00 and gave the company a "neutral" rating in a report on Friday, August 2nd. Canaccord Genuity Group initiated coverage on Tandem Diabetes Care in a report on Thursday, August 8th. They issued a "buy" rating and a $57.00 price target for the company. Morgan Stanley restated an "equal weight" rating and set a $45.00 price objective on shares of Tandem Diabetes Care in a report on Monday, September 23rd. Finally, Barclays increased their price target on Tandem Diabetes Care from $55.00 to $58.00 and gave the company an "overweight" rating in a report on Monday, August 5th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $55.13.

Tandem Diabetes Care Stock Performance

TNDM stock traded down $2.69 during trading on Thursday, hitting $34.81. The company had a trading volume of 1,817,704 shares, compared to its average volume of 1,604,985. The firm has a market cap of $2.28 billion, a PE ratio of -16.89 and a beta of 1.33. Tandem Diabetes Care has a 1-year low of $13.82 and a 1-year high of $53.69. The firm has a 50-day moving average price of $42.06 and a 200-day moving average price of $41.89. The company has a quick ratio of 2.38, a current ratio of 3.05 and a debt-to-equity ratio of 1.31.

Institutional Trading of Tandem Diabetes Care

Several hedge funds have recently modified their holdings of TNDM. Vanguard Group Inc. increased its stake in shares of Tandem Diabetes Care by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 7,052,570 shares of the medical device company's stock valued at $249,732,000 after buying an additional 30,664 shares during the period. Jennison Associates LLC boosted its position in shares of Tandem Diabetes Care by 98.1% during the first quarter. Jennison Associates LLC now owns 2,556,124 shares of the medical device company's stock worth $90,512,000 after buying an additional 1,265,534 shares during the period. Fred Alger Management LLC grew its stake in shares of Tandem Diabetes Care by 45.2% during the 2nd quarter. Fred Alger Management LLC now owns 2,174,107 shares of the medical device company's stock worth $87,595,000 after acquiring an additional 677,036 shares in the last quarter. Bellevue Group AG increased its stake in Tandem Diabetes Care by 2.0% in the 1st quarter. Bellevue Group AG now owns 2,031,888 shares of the medical device company's stock valued at $71,949,000 after buying an additional 39,571 shares during the last quarter. Finally, Brown Capital Management LLC raised its holdings in Tandem Diabetes Care by 29.9% during the first quarter. Brown Capital Management LLC now owns 954,567 shares of the medical device company's stock worth $33,801,000 after acquiring an additional 219,940 shares in the last quarter.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.